W
William S. Weintraub
Researcher at Christiana Care Health System
Publications - 563
Citations - 39419
William S. Weintraub is an academic researcher from Christiana Care Health System. The author has contributed to research in topics: Myocardial infarction & Percutaneous coronary intervention. The author has an hindex of 98, co-authored 535 publications receiving 36951 citations. Previous affiliations of William S. Weintraub include St. Vincent's Health System & Emory University.
Papers
More filters
Journal ArticleDOI
Potential of Missing Life-Threatening Arrhythmias After Limiting the Use of Cardiac Telemetry
Pranav Kansara,Kristi Jackson,Robert Dressler,Henry Weiner,Roger Kerzner,William S. Weintraub,Andrew J. Doorey +6 more
Journal ArticleDOI
Patients With Left Main Coronary Artery Vasospasm Inadvertently Undergoing Coronary Artery Bypass Grafting Surgery
Asim A. Mohammed,Andrew Yang,Kimberly Shao,Angela DiSabatino,Ray A. Blackwell,Michael K. Banbury,William S. Weintraub,Andrew J. Doorey +7 more
TL;DR: To the Editor: Left main coronary artery (LMCA) vasospasm induced by angiographic catheters during coronary angiography, although uncommon, is a recognized complication of this procedure.
Journal ArticleDOI
Impact of the Duett sealing device on quality of life and hospitalization costs for coronary diagnostic and interventional procedures: Results from the Study of Economic and Quality of Life substudy of the SEAL trial.
Zefeng Zhang,Elizabeth M. Mahoney,Gary Gershony,Stephen G. Ellis,Jorge F. Saucedo,J.David Talley,Ted Feldman,William S. Weintraub +7 more
TL;DR: The Simple and Effective Arterial Closure (SEAL) trial examined the safety and effectiveness of the Duett vascular sealing device (Vascular Solutions, Minneapolis, Minn) versus manual compression after diagnostic and interventional coronary procedures as mentioned in this paper.
Journal ArticleDOI
Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review
TL;DR: The comparative and cost effectiveness of different combinations of antiplatelet and antithrombotic therapy will be the focus of future expected clinical and economic assessments.
Journal ArticleDOI
Development of 2 Registry-Based Risk Models Suitable for Characterizing Hospital Performance on 30-Day All-Cause Mortality Rates Among Patients Undergoing Percutaneous Coronary Intervention
Jeptha P. Curtis,Lori L. Geary,Yongfei Wang,Jersey Chen,Elizabeth E. Drye,Laura M. Grosso,John A. Spertus,John S. Rumsfeld,William S. Weintraub,Frederick A. Masoudi,Ralph G. Brindis,Harlan M. Krumholz +11 more
TL;DR: These National Quality Forum endorsed registry-based models produce estimates of hospital risk-standardized 30-day all-cause PCI mortality rates for patients undergoing PCI.